Merck

Merck’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment

Retrieved on: 
수요일, 4월 3, 2024
Research, Technology, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, Biopsy, Algorithm, Entrepreneurship, Intelligence, Patient, Tumor microenvironment, Merck, Marie Cassidy, Cancer, AI, Spacecraft, Merck Group, Investment, Clinical trial, Drug development, Pathology, Therapy, Machine learning, Section 32, Spatial analysis, Medicine, Medical imaging

By integrating AI algorithms for prospective patient enrollment in clinical trials, Nucleai is spearheading a first-in-field approach to personalized medicine.

Key Points: 
  • By integrating AI algorithms for prospective patient enrollment in clinical trials, Nucleai is spearheading a first-in-field approach to personalized medicine.
  • Nucleai's platform tailors therapy strategies to the intricate cellular landscape of each patient, optimizing clinical trial participant selection.
  • Leveraging AI and machine learning (ML), Nucleai analyzes pathology images and spatial data at the cellular and tissue levels.
  • This innovation marks a shift in disease diagnosis and treatment, offering an in-depth contextual view that underpins the development of novel therapeutics.

JDRF T1D Fund, a Leading Disease-Focused Venture Philanthropy Fund, Appoints Sylvia Tobé as Managing Director

Retrieved on: 
수요일, 4월 3, 2024
Genetics, Diabetes, Philanthropy, Other Health, Biotechnology, Fund Raising, Pharmaceutical, Health, Foundation, Other Philanthropy, Neurology, Growth, Synthetic biology, T1D, Merck, University, Doctor of Philosophy, Investment, Harvard University, Autoimmune disease, Pharmaceutical industry

The JDRF T1D Fund, a venture philanthropy investment fund focused on curing type 1 diabetes (T1D), announced today that Sylvia Tobé, PhD had joined as a Managing Director based in Boston.

Key Points: 
  • The JDRF T1D Fund, a venture philanthropy investment fund focused on curing type 1 diabetes (T1D), announced today that Sylvia Tobé, PhD had joined as a Managing Director based in Boston.
  • Dr. Tobé will work alongside the T1D Fund’s other Managing Directors and members of the investment team to advance and broaden the T1D Fund's investment activities and capabilities.
  • Dr. Tobé has a decade of life sciences industry experience and joins from Omega Funds, where she served as a Principal on the investment team.
  • Dr. Tobé also provided scientific leadership for multiple discovery programs within the company's internal pipeline and in collaboration with Merck.

Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic

Retrieved on: 
수요일, 4월 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry

In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.

Key Points: 
  • In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
  • Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
  • Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
  • She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.

Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Officer

Retrieved on: 
수요일, 4월 3, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, United States of Europe, European Brain Council, DSM-IV codes, ALS, University, Huntington's disease, Merck, Fellow, Therapy, CMO, Multimedia, HD, Pharmaceutical industry

Ph.D., as its first Chief Medical Officer (CMO).

Key Points: 
  • Ph.D., as its first Chief Medical Officer (CMO).
  • In this role, Jina will lead all clinical development and medical affairs activities at Prilenia.
  • Ph.D., Chief Medical Officer at Prilenia (Photo: Business Wire)
    Jina has more than 30 years’ experience in both academic neurology practice and in global drug development at leading pharmaceutical companies and joins Prilenia from Exciva, a neurodegeneration-focused biotech, where she was Chief Medical Officer.
  • Ph.D., Chief Medical Officer of Prilenia.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer

Retrieved on: 
화요일, 4월 2, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Breast cancer, Goserelin, Patient, Lung, Social media, Immunoglobulin G, National Cancer Institute, Neoplasm, Merck & Co., TNBC, Capecitabine, DXD, BRCA, Clinical Cancer Research, Metabolism, Immunology, Biopharmaceutical, World Health Organization, Cancer, Safety, ADC, BLA, Daiichi Sankyo, Vinorelbine, IHC, Mutation, NSCLC, Disease, Merck, AKT, Death, MD, AstraZeneca, PARP, Oncotarget, PFS, FDA, OS, HER2, Eribulin, Cleavage, Progression-free survival, Triple-negative breast cancer, Female, Emerging, Olaparib, Biology, Sapporo Medical University, Medicine, Pharmaceutical industry

The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with that observed in other ongoing trials with no new safety concerns identified.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.
  • A comprehensive global clinical development program is underway with more than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC) and HR-positive, HER2-negative breast cancer.
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

Merck Foundation announced ‘‘Diabetes and Hypertension’’ Media Recognition Awards 2024 for Asian Countries

Retrieved on: 
수요일, 4월 3, 2024
Communications, Health, Diabetes, General Health, Other Communications, Media, Online, Hypertension, Merck, Subject, Prize money, Multimedia, Pharmaceutical industry

Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists from Asian Countries.

Key Points: 
  • Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists from Asian Countries.
  • View the full release here: https://www.businesswire.com/news/home/20240327714861/en/
    Merck Foundation announced ‘‘Diabetes and Hypertension’’ Media Recognition Awards 2024 for Asian Countries (Photo: Business Wire)
    The theme of the awards is to promote a healthy lifestyle and raise awareness about prevention and early detection of Diabetes and Hypertension.
  • Hence, I am inviting all media representatives from Asian Countries to participate for our Media Awards and share their most meaningful work that has helped raise awareness about diabetes and hypertension, and highlight the importance of leading a healthy lifestyle.”
    The awards are open to all the journalists in Asian Countries from Print, Online, Radio and Multimedia platforms.
  • Merck Foundation has also launched these awards for African and Latin American countries.

Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries

Retrieved on: 
수요일, 4월 3, 2024
Cardiology, Health, Media, Diabetes, Communications, Philanthropy, Consumer, Foundation, Online, Hypertension, Country, Merck, Subject, Prize money, Multimedia, Pharmaceutical industry

Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany, announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists in Latin American Countries.

Key Points: 
  • Merck Foundation ( www.merck-foundation.com ), the philanthropic arm of Merck KGaA Germany, announced the call for applications for their Media Recognition ‘Diabetes & Hypertension’ Awards 2024 for the journalists in Latin American Countries.
  • View the full release here: https://www.businesswire.com/news/home/20240327222745/en/
    Merck Foundation Announced "Diabetes and Hypertension" Media Recognition Awards 2024 for Latin American Countries (Graphic: Business Wire)
    The theme of the awards is to promote a healthy lifestyle and raise awareness about prevention and early detection of Diabetes and Hypertension.
  • Senator, Dr. Rasha Kelej, CEO of Merck Foundation emphasized, “Media plays a critical role in enhancing awareness in the public on critical health issues.
  • Merck Foundation has also launched these awards for African and Asian countries.

Cornerstone Building Brands Appoints Dr. Marcia Avedon to its Board of Directors

Retrieved on: 
화요일, 3월 26, 2024
Architecture, Residential Building & Real Estate, Manufacturing, Commercial Building & Real Estate, Construction & Property, Building Systems, Other Manufacturing, Anheuser-Busch, Ingersoll Rand, Growth, Generac, Merck & Co., Saint-Gobain, Merck, Communication, Corporate Affairs, Lincoln National Corporation, Marketing, Trane Technologies, Honeywell, Human resources, Acuity Brands, Management

Cornerstone Building Brands, Inc., a leading manufacturer of exterior building products in North America, has appointed Marcia Avedon, Ph.D., as a member of its board of directors (the “Board”), effective April 1, 2024.

Key Points: 
  • Cornerstone Building Brands, Inc., a leading manufacturer of exterior building products in North America, has appointed Marcia Avedon, Ph.D., as a member of its board of directors (the “Board”), effective April 1, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240326897081/en/
    Dr. Marcia Avedon will serve as a member of the Cornerstone Building Brands board of directors, effective April 1, 2024.
  • “Marcia’s depth and breadth of both corporate leadership and board experience in leadership development, talent and succession management, executive compensation, organizational development, corporate governance, brand building, operations and sustainability make her a particularly strong addition to our Cornerstone Building Brands board of directors,” said Rose Lee, President and Chief Executive Officer, Cornerstone Building Brands.
  • Marcia previously served on the board of directors of GCP Applied Technologies and Lincoln National Corporation.

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Retrieved on: 
화요일, 3월 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Carcinoma, Alkermes, Erasmus University Rotterdam, Cetuximab, Patient, SVP, ImClone Systems, Biostatistics, Merck, Epidemiology, Management, University, MBA, Merck Group, Limited partnership, MPH, Therapy, International school, PPD, Eli Lilly and Company, Marketing, Avelumab, Daiichi Sankyo

“We are very pleased to welcome Jeltje and Rita to our talented team.

Key Points: 
  • “We are very pleased to welcome Jeltje and Rita to our talented team.
  • Dr. Schulten received her medical degree from Erasmus University, Rotterdam, Netherlands and her MBA from the International School of Management RSM, Rotterdam, Netherlands.
  • Dr. Rita Dalal is a trained physician with extensive and diverse clinical research experience including in solid tumor oncology.
  • Previously, Dr. Dalal held clinical research scientist positions with Merck Sharp & Dohme Corp. and Eli Lilly and Company.

TaskUs and V7 Announce Strategic Partnership To Enable Enterprise AI Product Delivery

Retrieved on: 
월요일, 3월 25, 2024
Software, Technology, Artificial Intelligence, Data Management, Concept, Organization, Pressure, Health, Partnership, Fintech, SVP, Roche, GDPR, Social media, Merck, Miele, Bayer, Lawyer, Automated machine learning, Sony, DICOM, Production, Sales

TaskUs and V7 are combining their expertise in AI and data annotation to optimize training data creation for AI product development at some of the world’s biggest technology companies.

Key Points: 
  • TaskUs and V7 are combining their expertise in AI and data annotation to optimize training data creation for AI product development at some of the world’s biggest technology companies.
  • With a proven track record in supporting enterprise retail, healthcare, and asset management industries, the collaboration between V7 and TaskUs offers customers accelerated training data delivery, reduced production costs, and turnkey enterprise solutions.
  • The partnership aims to slash development cycles and enable enterprises to launch AI products significantly faster.
  • "We are thrilled about our strategic partnership with V7, marking a transformative phase in AI product development,” said Phil Tomlinson, SVP, of Global Offerings at TaskUs.